World Health Organization · 1st edition, 2026 · 26 pages
WHO guidance for integrating Taenia solium taeniasis and neurocysticercosis surveillance into routine health information systems.
- Issuer
- World Health Organization
- Edition
- 1st edition, 2026
- Audience
- Health ministry decision-makers, epidemiologists, national-level data managers, health facility data clerks, health workers working on T. solium control.
- Evidence
- Expert consensus; part of WHO routine health information system toolkit
- Reviewed
- 15 Oct 2026 · GMJ
What this guideline says
GMJ summary
This normative WHO guidance document provides a standardised framework for collecting, analysing, and reporting data on Taenia solium taeniasis and cysticercosis through routine health information systems. The document defines case definitions, core indicators, and reporting mechanisms to enable countries to monitor disease burden, track control programme progress, and report to WHO on neglected tropical disease (NTD) roadmap targets.
The guidance emphasises that T. solium is highly focal, affecting the poorest communities with inadequate sanitation and free-roaming pigs. Neurocysticercosis (NCC) is the leading cause of acquired epilepsy in low-income countries, accounting for approximately 30% of epilepsy cases in endemic areas. The document establishes thresholds for public health intervention: ≥0.5% T. solium taeniasis prevalence in humans or ≥2% porcine cysticercosis in pigs.
Critical safety guidance is provided: patients with suspected or confirmed NCC must not receive praziquantel or albendazole without neuroimaging and neurologist supervision, as these medicines can trigger serious adverse events in people with latent NCC. Niclosamide is recommended as a safe alternative for taeniasis treatment in patients with suspected NCC. The document advocates for a One Health approach integrating human health, animal health, and environmental sectors for sustainable control.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Public health intervention threshold: ≥0.5% <em>T. solium</em> taeniasis prevalence in humans or ≥2% porcine cysticercosis in pigs.
- Taeniasis treatment: single dose of praziquantel or niclosamide; albendazole requires 3 consecutive days of treatment.
- <strong>Critical safety warning</strong>: patients with suspected or confirmed NCC must not receive praziquantel or albendazole without neuroimaging (CT or MRI) and neurologist supervision.
- Niclosamide is safe for taeniasis treatment in patients with suspected/confirmed NCC because it is not absorbed and does not cross the blood–brain barrier.
- NCC diagnosis requires neuroimaging: MRI is preferred for most cases; CT is best for detecting small calcified lesions.
- NCC symptomatic treatment may include antiepileptic medicines and corticosteroids; anthelminthics only after imaging confirmation.
- Confirmed taeniasis case definition: identification of worm segments, eggs or antigens in stools confirmed by molecular or parasitological methods as <em>T. solium</em>.
- Data disaggregation required: by age group (<1 y, 1–4 y, 5–14 y, 15–24 y, 25–49 y, 50–64 y, ≥65 y), sex, residency status, and administrative unit.
Recommended minimum core indicators, definitions and disaggregation
Table extracted from the guideline
| Indicator | Definition | Disaggregation |
|---|---|---|
| Number of people at risk of T. solium | Number of people living in T. solium endemic areas | By administrative unit(s) |
| Number of suspected T. solium taeniasis cases | Number of people who show or report worm segments (proglottids) in faeces | By age group, sex, residency status, administrative units |
| Number of confirmed T. solium taeniasis cases | Worm segments, eggs or antigens in stools confirmed by molecular or parasitological methods as T. solium | By age group, sex, residency status, administrative units |
| Number of neurocysticercosis cases suspected | Person living in T. solium endemic area with neurological symptoms compatible with NCC | By age group, sex, residency status, administrative units |
| Number of neurocysticercosis cases probable | Person in endemic area with positive serology and clinical signs compatible with NCC | By age group, sex, residency status, administrative units |
| Number of neurocysticercosis cases confirmed | Case of NCC confirmed by imaging (CT scan or MRI) | By age group, sex, residency status, administrative units |
Source: World Health Organization, Routine health information system and health facility data for neglected tropical diseases: Taenia solium taeniasis and cysticercosis. Reproduced in summary form.
From the guideline
Verbatim
“Patients suspected to have neurocysticercosis must not be given praziquantel or albendazole without evaluation by imaging and neurologist supervision.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As someone who has worked on surveillance systems strengthening in the region, I recognise that this guidance addresses a genuine gap: the South Caucasus has pockets of small-scale pig farming where <em>T. solium</em> transmission may occur undetected. The critical safety warning about anthelminthic use in suspected neurocysticercosis is particularly important for our primary care colleagues who may encounter patients with unexplained seizures in rural areas. Georgia's relatively strong health information system infrastructure, developed through our tuberculosis and hepatitis C programmes, provides a foundation for integrating these indicators into routine reporting. However, the practical challenge will be access to neuroimaging outside Tbilisi and major cities—most district hospitals lack CT scanners, let alone MRI capacity. National programmes must first invest in mapping surveys to identify any endemic foci before implementing the full surveillance framework, and consider telemedicine consultations with neurologists for suspected cases in remote areas where immediate imaging is not available.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 15 Oct 2026
Applicability
Georgia and the South Caucasus
The South Caucasus region, including Georgia, Armenia, and Azerbaijan, has limited published data on T. solium endemicity, though small-scale pig farming and rural sanitation challenges exist in some areas. National programmes would need to conduct initial mapping surveys using the WHO protocols to determine endemic areas and establish baseline prevalence data. Implementation in Georgia would require strengthening neuroimaging capacity, particularly in rural areas, and training neurologists on NCC management protocols. The guidance on last-mile logistics for antiepileptic medicines is directly applicable to Georgia’s essential medicines programme, and the data collection framework could be integrated into the existing health information system infrastructure established for other NTDs and the national epilepsy programme.
Questions this guideline answers
Quick answers
Why can't we use praziquantel or albendazole freely for suspected taeniasis?
Both medicines cross the blood–brain barrier and can trigger serious adverse events in people with latent neurocysticercosis by causing an inflammatory response when cysts die. Patients must first be screened for neurological symptoms compatible with NCC, and if suspected, they need neuroimaging before receiving these anthelminthics. Niclosamide is a safe alternative because it is not absorbed.
What prevalence justifies starting a public health control programme?
WHO recommends starting public health interventions when prevalence reaches ≥0.5% <em>T. solium</em> taeniasis in the human population or ≥2% porcine cysticercosis in pigs. Given the focal nature and low prevalence of taeniasis, even a small number of positive cases should trigger surveillance to determine if this threshold has been reached.
How long after infection do neurocysticercosis symptoms appear?
The incubation period for NCC is highly variable, ranging from months to up to 30 years, although symptoms usually appear within 7–10 years. This means infected individuals can remain asymptomatic for many years, and changes in NCC case numbers following control interventions will only be observed over medium- to long-term time series.
What imaging is required to confirm neurocysticercosis?
MRI is the tool of choice for diagnosing NCC, particularly for viable parenchymal cysts, granulomas, and NCC in the cerebellum, brain stem, ventricular, subarachnoid, and spinal spaces. CT scan is the tool of choice for detecting small calcified lesions and should be used as an alternative where MRI is unavailable or contraindicated. Both can confirm the diagnosis.
Related on GMJ
Interconnected resources
Dictionary of Public Health
Conditions A–Z
GMJ News coverage
Quality & accreditation
Other guidelines on this topic
- Public health resource pack for countries experiencing outbreaks of influenza in animals
- Digital adaptation kit for birth defects surveillance: operational requirements for implementing WHO recommendations in digital systems
- Strategic actions for infection prevention and control and water, sanitation and hygiene during mpox outbreak response
- Digital adaptation kit for self-monitoring of blood pressure during pregnancy: operational requirements for implementing WHO recommendations in digital systems
- Behavioural and social drivers of influenza vaccination: tools and practical guidance for achieving high uptake
- Issuer
- World Health Organization
- Type
- Guidance (normative)
- Edition
- 1st edition, 2026
- Status
- Current
- Published
- 2026-07-31
- Languages
- English
- Scope
- Guidance on integrating T. solium taeniasis and cysticercosis data into routine health information systems for surveillance, case management monitoring, and reporting to WHO.
- Audience
- Health ministry decision-makers, epidemiologists, national-level data managers, health facility data clerks, health workers working on T. solium control.
- Pages
- 26
- Licence
- CC BY-NC-SA 3.0 IGO
- ISBN
- 978-92-4-012232-1
- Evidence
- Expert consensus; part of WHO routine health information system toolkit
- Record history
- Created 15 Oct 2026 · updated 15 Oct 2026 · next check Apr 2027
World Health Organization. Routine health information system and health facility data for neglected tropical diseases: Taenia solium taeniasis and cysticercosis. Geneva: World Health Organization; 2026. Licence: CC BY-NC-SA 3.0 IGO.GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
